Department of Paediatrics - Neonatology and Paediatric Cardiology, Addenbrooke's Hospital, NICU, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge School of Clinical Medicine, Box 402, Biomedical Campus, CB2 0QQ, Cambridge, UK.
Loma Linda University School of Medicine, Loma Linda, CA, USA.
Eur J Pediatr. 2022 Feb;181(2):813-821. doi: 10.1007/s00431-021-04275-w. Epub 2021 Oct 7.
Pulse oximetry screening (POS) has been shown to be an effective, non-invasive investigation that can detect up to 50-70% of previously undiagnosed congenital heart defects (CHDs). The aims of this study were to assess the accuracy of POS in detection of CHDs and its impact on clinical practice. All eligible newborn infants born between 1 Jan 2015 and 31 Dec 2019 in a busy regional neonatal unit were included in this prospective observational study. A positive POS was classified as two separate measurements of oxygen saturation < 95%, or a difference of > 2% between pre- and post-ductal circulations. Overall, 23,614 infants had documented POS results. One hundred eighty nine (0.8%) infants had a true positive result: 6 had critical CHDs, 9 serious or significant CHDs, and a further 156/189 (83%) infants had significant non-cardiac conditions. Forty-three infants who had a normal POS were later diagnosed with the following categories of CHDs post-hospital discharge: 1 critical, 15 serious, 20 significant and 7 non-significant CHDs. POS sensitivity for detection of critical CHD was 85.7%, whereas sensitivity was only 33% for detection of major CHDs (critical and serious) needing surgery during infancy; specificity was 99.3%.Conclusion: Pulse oximetry screening showed moderate to high sensitivity in detection of undiagnosed critical CHDs; however, it failed to detect two-third of major CHDs. Our study further emphasises the significance of adopting routine POS to detect critical CHDs in the clinical practice. However, it also highlights the need to develop new, innovative methods, such as perfusion index, to detect other major CHDs missed by current screening tools. What is Known: • Pulse oximetry screening is cost effective, acceptable, easy to perform and has moderate sensitivity and high specificity in detection of critical congenital heart defects. • Pulse oximetry screening has been implemented many countries including USA for detection of critical congenital heart defects, but it is not currently recommended by the UK National Screening Committee. What is New: • To our knowledge, this is the first study describing postnatal detection and presentation of all the infants with congenital heart defects over a period of 5 years, including those not detected on the pulse oximetry screening, on the clinical practice. • It emphasises that further research required to detect critical congenital heart defects and other major CHDs which can be missed on the screening tools currently employed in clinical practice.
脉搏血氧饱和度筛查(POS)已被证明是一种有效、非侵入性的检查方法,可检测到多达 50-70%以前未诊断出的先天性心脏病(CHD)。本研究的目的是评估 POS 在检测 CHD 中的准确性及其对临床实践的影响。所有符合条件的新生儿于 2015 年 1 月 1 日至 2019 年 12 月 31 日期间在一个繁忙的地区新生儿病房出生,均纳入本前瞻性观察研究。POS 阳性被定义为两次单独测量的氧饱和度<95%,或导管前和导管后循环之间的差异>2%。共有 23614 例婴儿记录了 POS 结果。189 例(0.8%)婴儿出现阳性结果:6 例有严重的 CHD,9 例严重或显著 CHD,156/189(83%)例婴儿有显著的非心脏疾病。43 例 POS 正常的婴儿在出院后被诊断出患有以下几类 CHD:1 例严重,15 例严重,20 例显著,7 例非显著 CHD。POS 对检测严重 CHD 的敏感性为 85.7%,而对检测婴儿期需要手术的严重和严重 CHD(严重和严重)的敏感性仅为 33%;特异性为 99.3%。结论:脉搏血氧饱和度筛查对检测未诊断的严重 CHD 具有中等到高度的敏感性;然而,它未能检测到三分之二的严重 CHD。我们的研究进一步强调了在临床实践中采用常规 POS 检测严重 CHD 的重要性。然而,它也突出了需要开发新的、创新的方法,如灌注指数,以检测当前筛查工具错过的其他严重 CHD。已知:•脉搏血氧饱和度筛查在检测严重先天性心脏病方面具有成本效益、可接受、易于实施、中度敏感性和高度特异性。•脉搏血氧饱和度筛查已在许多国家实施,包括美国,用于检测严重先天性心脏病,但目前英国国家筛查委员会不推荐使用。新内容:•据我们所知,这是第一项在 5 年内描述所有患有先天性心脏病的婴儿的产后检测和表现的研究,包括那些在脉搏血氧饱和度筛查中未被发现的婴儿,以及那些在临床实践中未被发现的婴儿。•它强调需要进一步研究以检测目前在临床实践中使用的筛查工具可能错过的严重先天性心脏病和其他严重 CHD。
Arch Dis Child Fetal Neonatal Ed. 2022-5
Cochrane Database Syst Rev. 2018-3-1
Am J Perinatol. 2024-5
Arch Dis Child Fetal Neonatal Ed. 2015-9
J Matern Fetal Neonatal Med. 2020-6
Int J Neonatal Screen. 2025-5-17
Curr Treat Options Cardiovasc Med. 2025
Children (Basel). 2025-3-15
Rev Esc Enferm USP. 2024
Int J Neonatal Screen. 2020-3-14
Lancet. 2020-9-26
Biomed Eng Online. 2020-5-14
Am J Perinatol. 2019-4-19
J Perinat Med. 2018-2-23